Clinical Efficacy of Piracetam in Cognitive Impairment: A Meta-Analysis

  title={Clinical Efficacy of Piracetam in Cognitive Impairment: A Meta-Analysis},
  author={Tony Waegemans and Colin R. Wilsher and Anne Danniau and Steven H. Ferris and Alexander Kurz and Bengt Winblad},
  journal={Dementia and Geriatric Cognitive Disorders},
  pages={217 - 224}
A meta-analysis has been performed including nineteen double blind, placebo controlled studies with piracetam in patients suffering from dementia or cognitive impairment in the elderly. These studies had as common outcome measure a clinical global impression of change, a measure of clinically meaningful improvement. The meta-analysis of this global outcome followed the methodology set forward by the Cochrane Collaboration. This article describes the studies, the patient populations and the… 

Figures and Tables from this paper

Effect of piracetam on the cognitive performance of patients undergoing coronary bypass surgery: A meta-analysis
Results indicated that piracetam may have been effective in improving the short-term cognitive performance of patients undergoing coronary bypass surgery.
Piracetam for dementia or cognitive impairment.
The evidence available from the published literature does not support the use of Piracetem in the treatment of people with dementia or cognitive impairment because effects were found only on global impression of change but not on any of the more specific measures.
Piracetam treatment in patients with cognitive impairment.
Chinese herbal medicine for Mild Cognitive Impairment and Age Associated Memory Impairment: a review of randomised controlled trials
An overall benefit on some outcome measures for the eight CHMs involved in the 10 RCTs but methodological and data reporting issues were evident.
Piracetam and Piracetam-Like Drugs
Assessing the clinical outcomes as well as the scientific literature relating to the pharmacology, pharmacokinetics/pharmacodynamics, mechanism of action, dosing, toxicology and adverse effects of marketed and investigational drugs indicate notable improvements in clinical outcomes with some of these agents.
Cerebroprotective effect of piracetam in patients undergoing open heart surgery.
  • S. Holinski, B. Claus, W. Konertz
  • Medicine, Psychology
    Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • 2011
Piracetam had no cerebroprotective effect in patients undergoing open heart surgery, and unlike the patients who underwent coronary surgery, piracetam did not reduce the early postoperative decline of neuropsychological abilities in heart valve patients.
The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan
Investigating the effects of anti-dementia and nootropic treatments on the mortality of dementia using a population-based cohort study found pharmacological treatments have beneficial effects for patients with dementia in prolonging their survival.
Treatment of the mild cognitive impairment (MCI)
Three hypotheses will be presented on the basis of the neurobiology and the pharmacology of mild cognitive impairment: MCI is a new entity, it could also be considered as a monosymptomatic syndrome (amnesia) leading to the development of pure pro‐mnestic drugs, and examples of potentially active candidates will be discussed.
Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review
From the data reported in the literature, it emerges that nootropics may be an effective alternative for strengthening and enhancing cognitive performance in patients with a range of pathologies.
Clinical trials in mild cognitive impairment: lessons for the future
Design of future clinical trials in MCI should be further developed particularly as regards the selection of more homogeneous samples at entry, optimal treatment duration, and multidimensional and reliable outcomes.


A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease
Although there was a significant improvement on one subtest of the functional scale, no significant effects were demonstrated in cognitive or neurological measures and the dose was increased to 4.8 g for an additional 12 weeks.
Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment
In a 12-week double-blind study, piracetam at two dose levels (2.4 and 4.8g/day) was compared to placebo in the treatment of 60 elderly psychiatric patients with mild diffuse cerebral impairment, but
A double blind investigation of piracetam (Nootropil) vs placebo in geriatric memory.
Fifty-six hospitalized geriatric patients between the ages of 65 and 80 were given piracetam (Nootropil) 2400 mg/day or placebo on a double blind basis over a two month period and there were no significant statistical differences.
A clinical and neurophysiological trial on nootropic drugs in patients with mental decline.
The different expressions of mental decline in elderly people, from simple senile benign forgetfulness to SDAT, can be evaluated by psychometric and neurophysiological tests. In the present study,
Defining Meaningful Change in Alzheimer's Disease Trials: The Donepezil Experience
The results from three pivotal trials investigating the acetylcholinesterase inhibitor, donepezil, are used to demonstrate the way in which these tools are used, how to interpret the data they provide, and to deter mine their overall value in ascertaining efficacy in clinical practice.
The Clinician Interview‐ Based Impression (CIBI)
Modifications of the CIBI that might improve its reliability and acceptance include (1) no restrictions on the form of the bedside mental status assessment, (2) inclusion of caregiver input, and (3) better definition of ratings on the global scale.
Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
The committee could not reach a consensus on whether global scales should be required in phase II and phase III clinical trials, or whether other specific assessments such as well-designed activities of daily living, cognition, and behavior measures could, when used in appropriate combinations, replace the global as assessments of clinical meaningfulness.
Clinical Global Impressions in Alzheimer's Clinical Trials
This article reviews the history of Clinical Global Impressions of Change (CGIC) instruments, their use and limitations in clinical trials of Alzheimer's disease, and the development of the National
Drug therapy and memory training programs: a double-blind randomized trial of general practice patients with age-associated memory impairment.
Combined therapy was most effective in patients whose baseline performance on memory tests was lowest, and the best results were observed with 4.8 g of piracetam, especially when training sessions began after 6 weeks of drug treatment.